


## Respiratory Pathogens Data Jul 27- Nov 2 2018



Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Mycoplasma	Chlamydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
OCT 26	0	0	2	0	18	23	93	1	8	2	3	6	1	157	2	506	0.4	n/a	n/a	1.6
OCT 19	0	0	1	0	12	25	93	1	5	3	3	6	0	149	1	415	0.2	0.8	0.5	1.3
OCT 12	0	0	0	0	11	17	111	1	4	3	0	1	1	149	0	478	0.0	0.6	0.4	0.4
OCT 6	0	0	1	0	4	15	101	2	5	1	2	2	0	133	1	435	0.2	0.8	0.4	0.4
SEP 28	0	0	0	0	1	10	103	2	1	2	2	3	0	124	0	410	0.0	0.9	0.6	1.5
SEP 21	0	0	0	0	1	10	107	1	6	3	3	0	2	133	0	388	0.0	0.8	0.9	0.9
SEP 14	0	0	0	0	2	9	135	0	2	0	5	1	0	154	0	415	0.0	0.7	1.0	0.7
SEP 7	0	0	0	0	0	9	113	0	4	0	1	1	0	128	0	370	0.0	1.7	0.5	0.9
AUG 31	0	0	1	0	1	6	84	1	3	1	5	0	0	102	1	338	0.3	1.8	0.7	0.7
AUG 24	0	1	0	0	1	3	67	1	0	0	2	0	0	75	1	258	0.4	1.6	0.2	6.9
AUG 17	0	0	0	0	0	8	42	1	1	2	1	0	1	56	0	267	0.0	0.3	1.2	2.3
AUG 10	0	0	2	0	0	6	55	2	2	1	1	1	0	70	2	246	0.8	0.9	0.2	3.4
AUG 3	0	0	0	0	0	5	35	1	5	0	0	0	0	46	0	229	0.0	1.0	0.2	0.0
JULY 27	0	0	0	0	0	12	44	1	8	1	2	1	1	70	0	288	0.0	1.0	0.2	0.0

Flu PCR  
% Rate

# ACL RESP. PANEL - POSITIVITY RATE AII 2018 - 31%

- All Corona
- Chla mydia
- Myco plasma
- All Para
- Adeno
- Meta pneumo
- EV / Rhino
- RSV
- Inf B
- InfA-H3
- 2009 H1N1
- InfA-H1
- Bocca





## Correlation between RPPNL (FLU PCR) and Sofia (FLUAG)

10/14/18 to 10/31/18				
FLUAG (Sofia) vs RPPNL (PCR) correlation				
		RPPNL		
		+	-	Total
FluAG	+	1	0	1
	-	1	157	158
		Total Duplicate tests		159
%				
50.0	Clinical Sensitivity			
100.0	Clinical Specificity			
100.0	Positive Predictive Value (PPV)			
99.4	Negative Predictive Value (NPV)			
99.4	Accuracy			


*Both positive samples were tested by two methods < 72 h apart*

10/28/18 to 11/3/18				
FLUAG (Sofia) vs RPPNL (PCR) correlation				
		RPPNL		
		+	-	Total
FluAG	+	0	0	0
	-	0	71	71
		Total Duplicate tests		71
%				
#DIV/0!	Clinical Sensitivity			
100.0	Clinical Specificity			
#DIV/0!	Positive Predictive Value (PPV)			
100.0	Negative Predictive Value (NPV)			
100.0	Accuracy			

*No positive samples were tested by two methods*

CDC Oct 27, 2018 **Positivity rate 0.6%** - Flu A – 61% , Flu B – 39%


### Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 1, 2017 – October 27, 2018



## A Weekly Influenza Surveillance Report Prepared by the Influenza Division


Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists\*

Week Ending Oct 27, 2018 - Week 43



\*This map indicates geographic spread and does not measure the severity of influenza activity.

## 2018-19 Influenza Season Week 43 ending Oct 27, 2018



### ILI Activity Level



\*This map uses the proportion of outpatient visits to healthcare providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.


\*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore may not accurately depict the full picture of influenza activity for the whole state.

\*Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.

\*Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.


\*For the data download you can use Activity Level for the number and Activity Level Label for the text description.

The most prevalent target as Nov 2<sup>nd</sup> were VZV and EV 7.4%







The most prevalent targets as Nov 2<sup>nd</sup> was **Giardia**



The most prevalent target as Nov 2<sup>nd</sup> was Norovirus



	BV-Bacterial vagionosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	<b>21.3</b>	<b>13.0</b>	<b>2.0</b>	<b>0.4</b>	<b>2.9</b>	<b>0.1</b>	<b>6.7</b>	<b>18.5</b>	<b>64.3</b>



Neuraminidase Inhibitors Resistance in Samples Collected – May 20- Oct 27, 2018,

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	<b>70</b>	<b>0</b>	<b>70</b>	<b>0</b>	<b>70</b>	<b>0</b>
Influenza A (H3N2)	<b>57</b>	<b>0</b>	<b>57</b>	<b>0</b>	<b>57</b>	<b>0</b>
Influenza B	<b>44</b>	<b>0</b>	<b>44</b>	<b>0</b>	<b>44</b>	<b>0</b>